Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients

Table 5

Other treatments received after ACT.

Patient	Other treatments received after TILs
	First	Response	Second	Response	Third	Response
1	NA	NA
2	Lilly study (tasisulam versus paclitaxel)	NA (study suspended)	Fote	NA	MEKi	SD
3	Fote	PD
4	None
5	Ipilimumab	PR	Ipilimumab	SD	Surg (single skin met)	CR
6	Fote DCB	CR
7	Ipilimumab	PR at 2 mo then PD
8	None
9	Carbo DCB	PD
10	Carbo DCB	SD	Ipilimumab	SD

Carbo: carboplatin; CR: complete response; DCB: dacarbazine; Fote: fotemustine; MEKi: MEK inhibitor; met: metastasis; mo: months; NA: data not available; PD: progressive disease; PR: partial response; SD: stable disease; Surg: surgery.